EnsoData is a startup that utilizes artificial intelligence to analyze the human body to diagnose health conditions. EnsoData, whose software uses machine learning algorithms to help clinicians score sleep data and diagnose patients with sleep apnea and other disorders, has now realized that dream—and then some. EnsoData's autoscoring algorithm combines AASM scoring best practices with cutting edge machine learning algorithms that learn and adapt to every single patient.
EnsoData is a startup that utilizes artificial intelligence to analyze the human body to diagnose health conditions. EnsoData, whose software uses machine learning algorithms to help clinicians score sleep data and diagnose patients with sleep apnea and other disorders, has now realized that dream—and then some. EnsoData's autoscoring algorithm combines AASM scoring best practices with cutting edge machine learning algorithms that learn and adapt to every single patient.
Invenra Inc. is a biopharmaceutical company specializing in the discovery of biologics, particularly antibodies and their derivatives. Founded in 2011 and located in Madison, Wisconsin, Invenra utilizes a proprietary technology that integrates cell-free expression of full-length antibodies with extreme miniaturization. This innovative approach allows for the screening of a vast number of full-length antibodies in phenotypic assays, facilitating the identification of next-generation biologics. The company boasts a strong scientific foundation and a team of experts with extensive knowledge in genomics, biochemistry, and bioengineering, blending advanced basic research with practical commercial applications.
HealthMyne, Inc., a healthcare informatics company, provides novel search, analytics, and imaging solutions to healthcare enterprises. It focuses on providing solutions to cancer care providers. The company’s smart imaging solutions deliver clinical decision support and quality assurance services to reduce diagnostic errors and increase clinical collaboration. Its technology provides physicians with tumor image manipulation, and EHR and image repository search capabilities for diagnosing and treating similar cases. HealthMyne, Inc. was founded in 2013 and is based in Madison, Wisconsin.
HealthMyne, Inc., a healthcare informatics company, provides novel search, analytics, and imaging solutions to healthcare enterprises. It focuses on providing solutions to cancer care providers. The company’s smart imaging solutions deliver clinical decision support and quality assurance services to reduce diagnostic errors and increase clinical collaboration. Its technology provides physicians with tumor image manipulation, and EHR and image repository search capabilities for diagnosing and treating similar cases. HealthMyne, Inc. was founded in 2013 and is based in Madison, Wisconsin.
FluGen, Inc. is a biopharmaceutical company focused on developing vaccines to prevent diseases caused by influenza viruses. Founded in 2007 and based in Madison, Wisconsin, FluGen offers RedeeFlu, a nasal spray vaccine designed to protect against influenza, along with a vaccine-loaded intradermal microneedle delivery device. The company aims to address both seasonal and pandemic influenza on a global scale.
Elucent Medical LLC is focused on enhancing breast cancer treatment through innovative solutions. Founded in 2014 and headquartered in Brookfield, Wisconsin, the company develops and commercializes a wireless marker tag and detection system designed to locate breast abnormalities during surgical excision. By improving the accuracy and efficiency of these procedures, Elucent Medical aims to elevate the quality of care while simultaneously lowering costs, making treatments more accessible and affordable for both healthcare providers and patients. The company leverages the expertise of entrepreneurs from medicine, technology, and business to bring forward effective healthcare innovations.
TAI Diagnostics, Inc. is a biotechnology company based in Wauwatosa, Wisconsin, specializing in non-invasive diagnostic tests for monitoring the health of transplanted organs in patients who have received solid organ transplants. Founded in 2013, the company focuses on utilizing cell-free DNA technology to enhance transplant surveillance, aiming to improve patient outcomes through highly sensitive diagnostic solutions. TAI Diagnostics is situated in the Milwaukee County Research Park, close to notable medical research institutions, which supports its mission to advance the field of organ transplant monitoring.
Madison Vaccines, Inc., a biopharmaceutical company, develops therapeutic plasmid DNA vaccines. It focuses on bone metastases and prostate cancer. The company is based in United States.
HealthMyne, Inc., a healthcare informatics company, provides novel search, analytics, and imaging solutions to healthcare enterprises. It focuses on providing solutions to cancer care providers. The company’s smart imaging solutions deliver clinical decision support and quality assurance services to reduce diagnostic errors and increase clinical collaboration. Its technology provides physicians with tumor image manipulation, and EHR and image repository search capabilities for diagnosing and treating similar cases. HealthMyne, Inc. was founded in 2013 and is based in Madison, Wisconsin.
Silatronix, Inc. is a company based in Madison, Wisconsin, specializing in the development of organosilicon (OS) compounds and formulations for energy storage applications. Founded in 2007, the company focuses on creating organosilicon electrolytes used in both rechargeable and non-rechargeable lithium-ion batteries, as well as in ultracapacitors. Silatronix combines expert knowledge in organosilicon chemistry with advancements in nanostructured electrodes and the electronic properties of materials, aimed at enhancing the performance and efficiency of energy storage devices. Its innovative products are integral to the evolving landscape of energy storage technology.
FluGen, Inc. is a biopharmaceutical company focused on developing vaccines to prevent diseases caused by influenza viruses. Founded in 2007 and based in Madison, Wisconsin, FluGen offers RedeeFlu, a nasal spray vaccine designed to protect against influenza, along with a vaccine-loaded intradermal microneedle delivery device. The company aims to address both seasonal and pandemic influenza on a global scale.
TAI Diagnostics, Inc. is a biotechnology company based in Wauwatosa, Wisconsin, specializing in non-invasive diagnostic tests for monitoring the health of transplanted organs in patients who have received solid organ transplants. Founded in 2013, the company focuses on utilizing cell-free DNA technology to enhance transplant surveillance, aiming to improve patient outcomes through highly sensitive diagnostic solutions. TAI Diagnostics is situated in the Milwaukee County Research Park, close to notable medical research institutions, which supports its mission to advance the field of organ transplant monitoring.
Silatronix, Inc. is a company based in Madison, Wisconsin, specializing in the development of organosilicon (OS) compounds and formulations for energy storage applications. Founded in 2007, the company focuses on creating organosilicon electrolytes used in both rechargeable and non-rechargeable lithium-ion batteries, as well as in ultracapacitors. Silatronix combines expert knowledge in organosilicon chemistry with advancements in nanostructured electrodes and the electronic properties of materials, aimed at enhancing the performance and efficiency of energy storage devices. Its innovative products are integral to the evolving landscape of energy storage technology.
FluGen, Inc. is a biopharmaceutical company focused on developing vaccines to prevent diseases caused by influenza viruses. Founded in 2007 and based in Madison, Wisconsin, FluGen offers RedeeFlu, a nasal spray vaccine designed to protect against influenza, along with a vaccine-loaded intradermal microneedle delivery device. The company aims to address both seasonal and pandemic influenza on a global scale.
NeuWave Medical develops tools that deliver energy to the human body to treat a variety of serious medical conditions. Their company founders are both engineers and physician-scientists which allows determining a clinical need and design solutions that are clinically relevant, effective, and minimally invasive. They strive to make the highest quality devices that are the products of choice for leading physicians and medical centers around the world. The company was founded in 2004 and is headquartered in Madison, Wisconsin.
HealthMyne, Inc., a healthcare informatics company, provides novel search, analytics, and imaging solutions to healthcare enterprises. It focuses on providing solutions to cancer care providers. The company’s smart imaging solutions deliver clinical decision support and quality assurance services to reduce diagnostic errors and increase clinical collaboration. Its technology provides physicians with tumor image manipulation, and EHR and image repository search capabilities for diagnosing and treating similar cases. HealthMyne, Inc. was founded in 2013 and is based in Madison, Wisconsin.
Madison Vaccines, Inc., a biopharmaceutical company, develops therapeutic plasmid DNA vaccines. It focuses on bone metastases and prostate cancer. The company is based in United States.
Thalchemy Corp. develops neurally-inspired algorithms and accelerators aimed at continuous sensory processing in smartphones and other battery-operated devices. By mimicking the functionality of the mammalian thalamus, the company's technology allows for the routing, filtering, and preprocessing of sensory data, which enhances the detection of complex gestures and hot words across multiple modalities. This innovative approach significantly extends battery life for devices such as smartphones and wearables, while providing optimized voice and gesture control. Thalchemy's solutions also support the creation of always-on applications, simplifying development through an automated, user-friendly interface. Additionally, the technology can monitor environmental conditions, enabling applications that alert users or caregivers in emergency situations, such as falls or irregular heartbeats. Founded in 2012 and based in Madison, Wisconsin, Thalchemy aims to transform user interfaces and experiences across a variety of sensing platforms.
Silatronix, Inc. is a company based in Madison, Wisconsin, specializing in the development of organosilicon (OS) compounds and formulations for energy storage applications. Founded in 2007, the company focuses on creating organosilicon electrolytes used in both rechargeable and non-rechargeable lithium-ion batteries, as well as in ultracapacitors. Silatronix combines expert knowledge in organosilicon chemistry with advancements in nanostructured electrodes and the electronic properties of materials, aimed at enhancing the performance and efficiency of energy storage devices. Its innovative products are integral to the evolving landscape of energy storage technology.
Thalchemy Corp. develops neurally-inspired algorithms and accelerators aimed at continuous sensory processing in smartphones and other battery-operated devices. By mimicking the functionality of the mammalian thalamus, the company's technology allows for the routing, filtering, and preprocessing of sensory data, which enhances the detection of complex gestures and hot words across multiple modalities. This innovative approach significantly extends battery life for devices such as smartphones and wearables, while providing optimized voice and gesture control. Thalchemy's solutions also support the creation of always-on applications, simplifying development through an automated, user-friendly interface. Additionally, the technology can monitor environmental conditions, enabling applications that alert users or caregivers in emergency situations, such as falls or irregular heartbeats. Founded in 2012 and based in Madison, Wisconsin, Thalchemy aims to transform user interfaces and experiences across a variety of sensing platforms.
Madison Vaccines, Inc., a biopharmaceutical company, develops therapeutic plasmid DNA vaccines. It focuses on bone metastases and prostate cancer. The company is based in United States.
Cellectar Biosciences is a clinical-stage biopharmaceutical company that specializes in the discovery, development, and commercialization of cancer therapies. The company’s lead candidate, CLR 131, is currently undergoing Phase II clinical trials for patients with relapsed or refractory multiple myeloma and various B-cell malignancies, alongside a Phase I study for the same indications. Cellectar is also advancing CLR 1900, a phospholipid drug conjugate chemotherapeutic program aimed at solid tumors. In addition, the company collaborates with several partners, including Pierre Fabre and Avicenna Oncology, to develop various PDC programs. Originally founded in 2002 and known as Novelos Therapeutics until its rebranding in 2014, Cellectar Biosciences has its headquarters in Florham Park, New Jersey, and is recognized for its innovative approach to combining lipid-like molecules and phospholipid ethers with radioisotopes for cancer treatment and imaging.
Silatronix, Inc. is a company based in Madison, Wisconsin, specializing in the development of organosilicon (OS) compounds and formulations for energy storage applications. Founded in 2007, the company focuses on creating organosilicon electrolytes used in both rechargeable and non-rechargeable lithium-ion batteries, as well as in ultracapacitors. Silatronix combines expert knowledge in organosilicon chemistry with advancements in nanostructured electrodes and the electronic properties of materials, aimed at enhancing the performance and efficiency of energy storage devices. Its innovative products are integral to the evolving landscape of energy storage technology.
Tissue Regeneration Systems Inc. is a start-up medical device company that commercializes a skeletal reconstruction and bone regeneration technology platform licensed from the Universities of Michigan and Wisconsin. Its technology platform is suited for various clinical applications in craniomaxillofacial surgery, orthopedic surgery, spine fusion surgery, and bone growth factor delivery markets. The company was incorporated in 2005 and is based in Plymouth, Michigan with an additional office in Kirkland, Washington. It has a research facility in Ann Arbor, Michigan.
Don’t let plans with friends slip through the cracks!
Nextt is a private network for close friends to connect online so they can do more together offline. Nextt simplifies the social planning process, letting you share ideas with friends and iron out the details (the Who, What, When and Where) in private. Use Nextt to get busy living and make quality time with your face-to-face friends a priority again.
NeuWave Medical develops tools that deliver energy to the human body to treat a variety of serious medical conditions. Their company founders are both engineers and physician-scientists which allows determining a clinical need and design solutions that are clinically relevant, effective, and minimally invasive. They strive to make the highest quality devices that are the products of choice for leading physicians and medical centers around the world. The company was founded in 2004 and is headquartered in Madison, Wisconsin.
Mithridion is a biopharmaceutical company that discovers and develops drugs for central nervous system disorders, with an initial focus on Alzheimer's disease and schizophrenia.
ProCertus BioPharm, Inc., an oncology-based pharmaceutical company, develops therapeutics to protect cancer patients from the side effects of radiotherapy and chemotherapy in the United States. Its products include ProDermaCel that protects cancer patients from chemotherapy- and radiotherapy-induced alopecia; DermX, which prevents radiotherapy-induced dermatitis; and OralX that provides protection against chemotherapy- and radiotherapy- induced oral mucositis. ProCertus BioPharm, Inc. was founded in 1997 and is based in Madison, Wisconsin.
Mithridion is a biopharmaceutical company that discovers and develops drugs for central nervous system disorders, with an initial focus on Alzheimer's disease and schizophrenia.
Silatronix, Inc. is a company based in Madison, Wisconsin, specializing in the development of organosilicon (OS) compounds and formulations for energy storage applications. Founded in 2007, the company focuses on creating organosilicon electrolytes used in both rechargeable and non-rechargeable lithium-ion batteries, as well as in ultracapacitors. Silatronix combines expert knowledge in organosilicon chemistry with advancements in nanostructured electrodes and the electronic properties of materials, aimed at enhancing the performance and efficiency of energy storage devices. Its innovative products are integral to the evolving landscape of energy storage technology.
Tissue Regeneration Systems Inc. is a start-up medical device company that commercializes a skeletal reconstruction and bone regeneration technology platform licensed from the Universities of Michigan and Wisconsin. Its technology platform is suited for various clinical applications in craniomaxillofacial surgery, orthopedic surgery, spine fusion surgery, and bone growth factor delivery markets. The company was incorporated in 2005 and is based in Plymouth, Michigan with an additional office in Kirkland, Washington. It has a research facility in Ann Arbor, Michigan.
At Nerites, they combine world class technology with a management team that has a proven track record of bringing technical innovation to market. The company was founded in 2004 to commercialize a new generation of synthetic biomaterials that can enhance natural tissue repair, reduce complications from traditional devices, and degrade safely when they are no longer needed.
NeuWave Medical develops tools that deliver energy to the human body to treat a variety of serious medical conditions. Their company founders are both engineers and physician-scientists which allows determining a clinical need and design solutions that are clinically relevant, effective, and minimally invasive. They strive to make the highest quality devices that are the products of choice for leading physicians and medical centers around the world. The company was founded in 2004 and is headquartered in Madison, Wisconsin.
Cellectar Biosciences is a clinical-stage biopharmaceutical company that specializes in the discovery, development, and commercialization of cancer therapies. The company’s lead candidate, CLR 131, is currently undergoing Phase II clinical trials for patients with relapsed or refractory multiple myeloma and various B-cell malignancies, alongside a Phase I study for the same indications. Cellectar is also advancing CLR 1900, a phospholipid drug conjugate chemotherapeutic program aimed at solid tumors. In addition, the company collaborates with several partners, including Pierre Fabre and Avicenna Oncology, to develop various PDC programs. Originally founded in 2002 and known as Novelos Therapeutics until its rebranding in 2014, Cellectar Biosciences has its headquarters in Florham Park, New Jersey, and is recognized for its innovative approach to combining lipid-like molecules and phospholipid ethers with radioisotopes for cancer treatment and imaging.
Deltanoid Pharmaceuticals, Inc. is a biopharmaceutical company that engages in the research, development, and commercialization of therapies for the treatment of renal diseases, osteoporosis, skin diseases, and other targets. It focuses on vitamin D analogs and other compounds to develop selected therapies through early phases of the drug development process. The company’s product includes DP001 for the treatment of secondary hyperparathyroidism in patients with chronic kidney disease receiving hemodialysis. It also develops DP006 for the treatment of acne. The company was founded in 1999 and is based in Madison, Wisconsin.
Virent Energy Systems, Inc. is an energy technology company based in Madison, Wisconsin, specializing in the production of hydrocarbon chemicals and fuels from plant sugars. Utilizing its patented BioForming technology, Virent converts various bio-based feedstocks, such as beet sugar, sugar cane, corn starch, and cellulosic materials like bagasse and corn stover, into products that are chemically identical to petroleum-derived fuels and chemicals. The company’s offerings include gasoline, diesel, jet fuel, and bio-aromatic compounds used in a variety of applications, such as paints, textiles, and automotive products. Virent has established strategic partnerships with notable companies, including Royal Dutch Shell and The Coca-Cola Company, to further its mission of providing renewable alternatives to fossil fuels. Founded in 2002, Virent operates as a subsidiary of Marathon Petroleum Corporation.
ProCertus BioPharm, Inc., an oncology-based pharmaceutical company, develops therapeutics to protect cancer patients from the side effects of radiotherapy and chemotherapy in the United States. Its products include ProDermaCel that protects cancer patients from chemotherapy- and radiotherapy-induced alopecia; DermX, which prevents radiotherapy-induced dermatitis; and OralX that provides protection against chemotherapy- and radiotherapy- induced oral mucositis. ProCertus BioPharm, Inc. was founded in 1997 and is based in Madison, Wisconsin.
Mithridion is a biopharmaceutical company that discovers and develops drugs for central nervous system disorders, with an initial focus on Alzheimer's disease and schizophrenia.
Virent Energy Systems, Inc. is an energy technology company based in Madison, Wisconsin, specializing in the production of hydrocarbon chemicals and fuels from plant sugars. Utilizing its patented BioForming technology, Virent converts various bio-based feedstocks, such as beet sugar, sugar cane, corn starch, and cellulosic materials like bagasse and corn stover, into products that are chemically identical to petroleum-derived fuels and chemicals. The company’s offerings include gasoline, diesel, jet fuel, and bio-aromatic compounds used in a variety of applications, such as paints, textiles, and automotive products. Virent has established strategic partnerships with notable companies, including Royal Dutch Shell and The Coca-Cola Company, to further its mission of providing renewable alternatives to fossil fuels. Founded in 2002, Virent operates as a subsidiary of Marathon Petroleum Corporation.
ZyStor Therapeutics, Inc. is a privately-held biotechnology company developing enzyme replacement therapies for the treatment of lysosomal storage diseases.
Roche NimbleGen provides products and services to the life science research market. The company offers SeqCap EZ system, a solution-based capture system that enables enrichment of exome in a single test tube; SeqCap EZ library that covers exome designs, gene panels, and custom content designs; and SeqCap EZ reagents to maximize workflow and order different reagent needs. It also provides SeqCap Epi, an enrichment system that includes a set of target enrichment tools for DNA methylation assessment at single-base resolution, as well as offers SeqCap Epi kits and reagents. The company provides a set of preparation and adapter kits for library construction including SignalMap, a software product for browsing of genomic tracks; and NimbleDesign, an online tool that enables users to design SeqCap EZ choice libraries. It offers DNA microarray products and services for CGH, ChIP-chip, DNA methylation, AccuSNP, CGS, instruments, sequence capture arrays, gene expression microarrays, and their associated workflows. The company also provides online technical and instruction support services. Roche NimbleGen was founded in 1999 and is headquartered in Madison, Wisconsin. As of August 8, 2007, Roche NimbleGen operates as a subsidiary of Roche Holding AG.
Roche NimbleGen provides products and services to the life science research market. The company offers SeqCap EZ system, a solution-based capture system that enables enrichment of exome in a single test tube; SeqCap EZ library that covers exome designs, gene panels, and custom content designs; and SeqCap EZ reagents to maximize workflow and order different reagent needs. It also provides SeqCap Epi, an enrichment system that includes a set of target enrichment tools for DNA methylation assessment at single-base resolution, as well as offers SeqCap Epi kits and reagents. The company provides a set of preparation and adapter kits for library construction including SignalMap, a software product for browsing of genomic tracks; and NimbleDesign, an online tool that enables users to design SeqCap EZ choice libraries. It offers DNA microarray products and services for CGH, ChIP-chip, DNA methylation, AccuSNP, CGS, instruments, sequence capture arrays, gene expression microarrays, and their associated workflows. The company also provides online technical and instruction support services. Roche NimbleGen was founded in 1999 and is headquartered in Madison, Wisconsin. As of August 8, 2007, Roche NimbleGen operates as a subsidiary of Roche Holding AG.
Roche NimbleGen provides products and services to the life science research market. The company offers SeqCap EZ system, a solution-based capture system that enables enrichment of exome in a single test tube; SeqCap EZ library that covers exome designs, gene panels, and custom content designs; and SeqCap EZ reagents to maximize workflow and order different reagent needs. It also provides SeqCap Epi, an enrichment system that includes a set of target enrichment tools for DNA methylation assessment at single-base resolution, as well as offers SeqCap Epi kits and reagents. The company provides a set of preparation and adapter kits for library construction including SignalMap, a software product for browsing of genomic tracks; and NimbleDesign, an online tool that enables users to design SeqCap EZ choice libraries. It offers DNA microarray products and services for CGH, ChIP-chip, DNA methylation, AccuSNP, CGS, instruments, sequence capture arrays, gene expression microarrays, and their associated workflows. The company also provides online technical and instruction support services. Roche NimbleGen was founded in 1999 and is headquartered in Madison, Wisconsin. As of August 8, 2007, Roche NimbleGen operates as a subsidiary of Roche Holding AG.
Corona Optical Systems is a Midwest-based high-technology company with headquarters in Lombard, Illinois. Additional facilities are located in Eau Claire, Wisconsin and San Jose, California. Corona's key technologies focus on high-speed optoelectronic components and subsystems for carrier-class equipment. Founded in February 2000, Corona is a privately held, venture capital funded corporation. Following an initial angel round, Corona completed its first institutional investment round in March 2001. Funds raised in this Series A round totaled $12.4 Million. Led by Intel Capital, this round included Chicago based venture capital firm KB Partners, Madison, Wisconsin based Venture Investors and the Geometry Group of New York City.
SoftSwitching Technologies offer the most affordable, effective and scalable power quality and monitoring solutions available on the market. A full array of scalable, battery-free DySC products. I-Sense intelligent sensors that pinpoint time and duration of voltage sags. And Grid Alert™ event notifications—the only global power reporting and notification network in the world.
Gala Biotech, a Catalent Pharma Solutions Company, was established in 1996 from technology developed at the University of Wisconsin. Located in Middleton, Wisconsin, this rapidly growing company (currently over 40 employees, including 16 PhD’s) has a wide range of capabilities in the fields of molecular biology, vector biology, cell line development, biopharmaceutical manufacturing, protein biochemistry, and quality systems. Gala’s core proprietary technology is GPEx® (Gene Product Expression), a gene insertion/expression technology that allows rapid creation of stable, high-expressing mammalian cell lines for a wide variety of gene products. "Gala" is Greek for milk, and the company's original mission was to produce pharmaceutical proteins in the milk of transgenic cows. The gene insertion technology that Gala developed to generate transgenic animals became the basis of Gala's Gene Product Expression or GPEx® technology for production of recombinant proteins in mammalian cell culture. The genomics revolution has led to the identification of thousands of new genes, and the race is now on to discover, characterize and stably express the protein products of these genes in order to develop new therapeutic proteins. Gala's GPEx® technology, when applied to mammalian cell culture, accelerates this process for its biopharmaceutical partners. Once new therapeutic proteins have been identified for clinical development, production support becomes a major challenge. Gala's mission is to meet this need, and the company has recently established a 43,000 square-foot facility in Middleton, Wisconsin devoted to GPEx®-based cell line development and cGMP-compliant protein production.
Alfalight designs and manufactures high-power diode lasers for the industrial, defense, and telecommunications markets. Alfalight's innovative technology is based on advanced aluminum-free active region (ALFA) laser structures, enabling the manufacture of laser diodes with exceptionally high reliability and industry-leading efficiency.
TomoTherapy develops, markets and sells advanced radiation therapy solutions that can be used to treat a wide variety of cancers, from the most common to the most complex. The ring gantry-based TomoTherapy:registered: platform combines integrated CT imaging with conformal radiation therapy to deliver sophisticated radiation treatments with speed and precision while reducing radiation exposure to surrounding healthy tissue. TomoTherapy’s suite of solutions include its Hi·Art:registered: treatment system, which has been used to deliver more than three million CT-guided, helical intensity-modulated radiation therapy (IMRT) treatment fractions; the TomoHD:tm: treatment system, designed to enable cancer centers to treat a broader patient population with a single device; and the TomoMobile:tm: relocatable radiation therapy solution, designed to improve access and availability of state-of-the-art cancer care. As of February 2011, there are more than 350 TomoTherapy systems in use in 24 countries worldwide. TomoTherapy’s stock is traded on the NASDAQ Global Select Market under the symbol TOMO. To learn more about TomoTherapy, please visit TomoTherapy.com.
Third Wave Technologies, Inc. engages in the development and marketing of molecular diagnostic products for various DNA and RNA analysis applications. It provides physicians and researchers with molecular solutions for the analysis and treatment of disease. The company offers products based proprietary Invader chemistry, a technology used in women's health, infectious disease, genetics and pharmacogenetics, and oncology segments. Third Wave principally offers inVitro diagnostic devices and analyte specific reagents. The company's analyte specific reagents allow laboratories to create assays to perform hepatitis C virus genotyping, inherited disorders testing, and a host of other mutations associated with genetic predispositions and other diseases. Third Wave also develops various DNA and RNA analysis products for the research and agricultural biotechnology markets. Its customers include clinical laboratories, pharmaceutical and biotechnology companies, academic research centers, and health care providers. Third Wave sells its products through a combination of direct sales personnel who focuses primarily on the clinical market, as well as through collaborative relationships in the United States and Europe. The company was founded in 1993 and is headquartered in Madison, Wisconsin. As of July 23, 2008, Third Wave Technologies Inc. operates as a subsidiary of Hologic Inc.
Promega Corporation, founded in 1978 and based in Madison, Wisconsin, specializes in manufacturing reagents and instrumentation for research, pharmaceutical, and diagnostics laboratories. The company offers over 2,000 products that support various applications, including cell biology, nucleic acid analysis, protein analysis, and molecular diagnostics. Its solutions are utilized in fields such as drug discovery, clinical research, forensic analysis, and human identification. In addition to standard products, Promega provides custom manufacturing, assay development, automation solutions, and quality control services. The company distributes its products globally through a network of distributors, reflecting its commitment to advancing scientific research and medical diagnostics.